| 朱焕焕,陈 志.政府支持科技型中小企业创新的国际经验及借鉴——以德国 BioNTech 为例[J].全球科技经济瞭望,2022,37(11):1~5 |
| 政府支持科技型中小企业创新的国际经验及借鉴——以德国 BioNTech 为例 |
| The International Experience and Reference of theGovernment's Support for Innovation of SMEs:A Case Study of BioNTech in Germany |
| 投稿时间：2022-09-03 |
| DOI：10.3772/j.issn.1009-8623.2022.11.001 |
| 中文关键词: 中国科学技术发展战略研究院 |
| 英文关键词: Germany; technological SMEs; COVID-19 vaccine R&D; BioNTech |
| 基金项目:项目来源：科技部科技创新战略研究专项“企业创新主体地位和创新联合体建设重大问题研究”（ZLY202252）。 |
|
| 摘要点击次数: 920 |
| 全文下载次数: 702 |
| 中文摘要: |
| 支持科技型中小企业创新发展是世界各国的普遍做法。本文以在全球新冠疫苗研发竞争中脱颖而出的科技型中小企业德国生物新技术公司拜恩泰科（BioNTech）为例，分析其利用信使核糖核酸（mRNA）免疫疗法共性技术成功研发新冠疫苗的主要因素以及德国政府支持企业新冠疫苗研发的主要方式。最后，结合我国实际，提出了未来加强我国科技型中小企业技术创新，尤其是突破关键共性技术的几点建议措施。 |
| 英文摘要: |
| It is a common practice for countries all over the world to support the small and medium-sized
enterprises (SMEs). This paper takes the German company BioNTech, a technology-based SMEs that has
emerged in the global COVID-19 vaccine R&D competition, as an example, to analyze the main factors of its
successful R&D of COVID-19 vaccine by using the common technology of mRNA immunotherapy and the main
ways in which the German government supports the R&D of COVID-19 vaccine. Finally, combined with the
actual situation of China, this paper puts forward some suggestions and measures to strengthen the technological
innovation, especially to break through the key generic technologies of the technological SMEs in China. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
